中国医药导刊
中國醫藥導刊
중국의약도간
CHINESE JOURNAL OF MEDICAL GUIDE
2012年
12期
2119-2120
,共2页
二甲双胍%胰岛素%2型糖尿病%血糖控制%低血糖
二甲雙胍%胰島素%2型糖尿病%血糖控製%低血糖
이갑쌍고%이도소%2형당뇨병%혈당공제%저혈당
Insulin%Metformin%Type 2 diabetes%Blood glucose control%Hypoglycemia
目的:探讨二甲双胍联合诺和锐30R对2型糖尿病患者血糖控制及低血糖的影响.方法:100例2-型糖尿病患者分为治疗组和对照组,对照组采用诺和锐30R早晚皮下注射治疗,治疗组在对照组的基础上口服二甲双胍治疗,比较两组患者的血糖控制情况及低血糖多发生情况.结果:治疗组治疗后的总有效率为84.0%显著高于对照组的总有效率为68.0%(P<0.05).两组治疗后空腹血糖、餐后2h血糖、睡前血糖、HbAlc的含量均较治疗前显著改善,但治疗组的改善效果显著优于对照组(P<0.05).且治疗组的诺和锐30R用量少于对照组,低血糖的发生率低于对照组(P<0.05).结论:二甲双胍联合诺和锐30R能够显著控制2型糖尿病患者的血糖水平,显著减少诺和锐30R的用量,降低低血糖的发生.
目的:探討二甲雙胍聯閤諾和銳30R對2型糖尿病患者血糖控製及低血糖的影響.方法:100例2-型糖尿病患者分為治療組和對照組,對照組採用諾和銳30R早晚皮下註射治療,治療組在對照組的基礎上口服二甲雙胍治療,比較兩組患者的血糖控製情況及低血糖多髮生情況.結果:治療組治療後的總有效率為84.0%顯著高于對照組的總有效率為68.0%(P<0.05).兩組治療後空腹血糖、餐後2h血糖、睡前血糖、HbAlc的含量均較治療前顯著改善,但治療組的改善效果顯著優于對照組(P<0.05).且治療組的諾和銳30R用量少于對照組,低血糖的髮生率低于對照組(P<0.05).結論:二甲雙胍聯閤諾和銳30R能夠顯著控製2型糖尿病患者的血糖水平,顯著減少諾和銳30R的用量,降低低血糖的髮生.
목적:탐토이갑쌍고연합낙화예30R대2형당뇨병환자혈당공제급저혈당적영향.방법:100례2-형당뇨병환자분위치료조화대조조,대조조채용낙화예30R조만피하주사치료,치료조재대조조적기출상구복이갑쌍고치료,비교량조환자적혈당공제정황급저혈당다발생정황.결과:치료조치료후적총유효솔위84.0%현저고우대조조적총유효솔위68.0%(P<0.05).량조치료후공복혈당、찬후2h혈당、수전혈당、HbAlc적함량균교치료전현저개선,단치료조적개선효과현저우우대조조(P<0.05).차치료조적낙화예30R용량소우대조조,저혈당적발생솔저우대조조(P<0.05).결론:이갑쌍고연합낙화예30R능구현저공제2형당뇨병환자적혈당수평,현저감소낙화예30R적용량,강저저혈당적발생.
Objective:To investigate the effects of metformin combined with aspart30R on glucose control and hypoglycemia in type 2 diabetic patients. Methods:100 cases of type 2 diabetes patients were divided into the treatment group and the control group, the control group was given aspart30R sooner or later subcutaneous injection therapy, the treatment group was given metformin on the basis of the control group, two groups were compared with blood glucose control and hypoglycemia occurs condition.Results:After treatment, the total efficiency in the treatment group was 84%which was higher than 68%in the control group (P<0.05). fasting blood glucose, postprandial blood glucose,2h bedtime blood glucose, the content of HbAlc in two groups were significantly improved, but the improvement in the treatment group were significantly better than the control group (P<0.05). The aspart30R dosage and treatment group was less than that in the control group, the incidence of hypoglycemia was lower than that of control group (P<0.05). Conclusion:Metformin combined with aspart30R on type 2 diabetes patients can obviously control the blood glucose level, significantly reduce the amount of aspart30R, and reduce the occurrence of hypoglycemia.